The first Alzheimer's drug approved in the United States

Category Drugs and medications for seniors

The first Alzheimer's drug approved in the United States

While current treatments for Alzheimer's disease focus on managing symptoms, a drug aimed at slowing the progression of the disease has just been approved by the U.S. Food and Drug Administration (FDA). Amid promises, effectiveness, and limitations, what does this new drug represent in the fight against Alzheimer's disease?

How does aduhelm act against Alzheimer's disease?

It is important to note that Alzheimer's disease is characterized by two physiological features in the brain: the presence of senile plaques and neurofibrillary degeneration. While some risk factors are identified, there is currently no specific known cause for these mechanisms associated with the disease. Senile plaques are primarily composed of a peptide called amyloid, which is normally present in the body but tends to aggregate and form senile plaques in the brains of individuals with the disease, continually increasing in number.

Find YOUR ideal care home NOW!

The new drug, manufactured by the pharmaceutical company Biogen, is designed to target the abnormal accumulation of this protein, beta-amyloid. Aduhelm, or Aducanumab, named after the molecule it utilizes, belongs to the class of monoclonal antibody treatments.

This monoclonal antibody is used to combat the beta-amyloid protein responsible for various dysfunctions underlying the disease. This new treatment revives the concept of immunotherapy in the fight against Alzheimer's disease. It is administered intravenously once a month and is estimated to cost $56,000 per year per person, with the possibility of reimbursement depending on the type of health coverage each patient has.

The first Alzheimer's treatment approved since 2003

This recent FDA approval makes Aduhelm the first treatment for Alzheimer's disease approved by the U.S. agency in eighteen years. Importantly, it is the first drug to target the disease itself and cognitive decline, rather than just its symptoms or various behavioral disorders. Several factors weighed in before this authorization was granted.

However, the FDA attached a conditional approval to the treatment, indicating that it must continue to prove its efficacy. Biogen has been asked to continue its clinical trials to confirm the benefits of Aduhelm and provide additional details, such as the ideal patient profile and the most appropriate dosage.

What are the benefits and limitations of aducanumab?

While Aduhelm represents a significant development in the fight against Alzheimer's disease, its recent approval for the U.S. market has not yet garnered unanimous support among experts. The lack of proven effectiveness has been a point of contention. The FDA justified its approval by citing the "urgent need for treatment" and the clear willingness of patients to accept a certain level of uncertainty in using a treatment that could potentially "have significant effects." Various scientific opinions on the use of this medication have emerged. While there is no doubt that this authorization marks a significant step in Alzheimer's disease research, enthusiasm must be tempered. It is by no means a "miracle cure" for the disease. Clinical trials in Phase III have indeed shown a 23% reduction in beta-amyloid plaques and cognitive decline. However, some experts emphasize that this treatment primarily slows cognitive decline rather than curing the disease. Furthermore, the treatment's efficacy appears to be mainly relevant for patients in the early stages of the disease, those with mild cognitive impairment and mild dementia.

It should also be noted that some seemingly reversible and infrequent side effects have been identified, and the medication must be closely monitored by a healthcare professional during treatment. These side effects primarily include headaches, falls, allergic reactions, and occasionally the risk of brain edema or microbleeds, which require careful monitoring. However, the benefit-to-risk ratio led the FDA to authorize the treatment based on the "consistent and highly persuasive" reduction in plaques.

Benefits and Limitations of Aduhelm

Aspect	Benefits	Limitations
Cognitive Impact	Reduces beta-amyloid plaques, potentially slowing cognitive decline.	Does not cure Alzheimer's; effectiveness is debated among experts.
Target Patients	Best suited for early-stage Alzheimer's patients.	Limited effectiveness for advanced-stage patients.
Side Effects	Generally mild; mostly headaches, falls, and allergic reactions.	Potential risk of brain edema and microbleeds requiring close monitoring.
Long-Term Efficacy	Represents a new path for future Alzheimer's treatments.	Further clinical trials needed to confirm its long-term benefits.

While the FDA's authorization of Aducanumab does not yet signify the eradication of Alzheimer's, and we cannot celebrate defeating the disease, it does bring great hope. Above all, it allows us to hope that this significant discovery represents the beginning of a new path toward a series of advancements leading to the optimal outcome.

FAQ:

1. What is Aduhelm (Aducanumab) and how does it work?
Aduhelm is a monoclonal antibody designed to target and reduce beta-amyloid plaques in the brain, which are linked to Alzheimer's disease. It aims to slow cognitive decline rather than cure the condition.

2. Who is eligible for Aduhelm treatment?
The drug is primarily recommended for individuals in the early stages of Alzheimer’s, including those with mild cognitive impairment or mild dementia.

3. What are the main side effects of Aduhelm?
Common side effects include headaches, dizziness, falls, and allergic reactions. More serious but rare side effects include brain swelling (edema) and microbleeds, requiring medical supervision.

4. Why is Aduhelm controversial?
While the FDA approved the drug, many experts question its efficacy. Clinical trials showed a 23% reduction in beta-amyloid plaques, but the degree of cognitive improvement remains debated.

5. How much does Aduhelm cost?
The treatment costs approximately $56,000 per year per patient. Reimbursement eligibility depends on the patient’s health insurance or national healthcare policies.

6. Is Aduhelm a cure for Alzheimer’s?
No, Aduhelm does not cure Alzheimer’s. It is designed to slow the progression of the disease, particularly in its early stages.

7. What is the future of Alzheimer’s treatments after Aduhelm?
The approval of Aduhelm marks an important step in Alzheimer’s research. Scientists hope this breakthrough will lead to further advancements and more effective treatments in the future.

We are here to help you choose a care home or facility best suited to your needs. Do not hesitate to contact us on the following number: 0230 608 0055 or fill out this form.